Real-time Monitoring of Hypertrophy in HL-1 Cardiomyocytes by Impedance Measurements Reveals Different Modes of Growth

Overview

Journal Cytotechnology

Specialties Biotechnology
Genetics

Date 2016 Jul 7

PMID 27380966

Citations 5

Authors

Laura Bloch

Bernadin Ndongson-Dongmo

Angelika Kusch

Duska Dragun

Regine Heller

Otmar Huber

Affiliations

Soon will be listed here.

Abstract

Hypertrophic growth is a response of the heart to increased mechanical load or physiological stress. Thereby, cardiomyocytes grow in length and/or width to maintain cardiac pump function. Major signaling pathways involved in cardiomyocyte growth and remodeling have been identified during recent years including calcineurin-NFAT and PI3K-Akt signaling. Modulation of these pathways is of certain interest for therapeutic treatment of cardiac hypertrophy. However, quantification and characterization of hypertrophy in response to different stimuli or modulators is difficult. This study aims to test different read-out systems for detection and quantification of differences in hypertrophic growth in response to prohypertrophic stimuli. Real-time impedance measurements allowed the detection of distinct differences in hypertrophic growth in response to endothelin, norepinephrine, phenylephrine or BIO, which were not observable by other methods such as flow cytometry. Endothelin treatment induced a rapid and strong peak in the impedance signal concomitant with a massive reorientation of the actin cytoskeleton. Changes in expression of hypertrophy-associated genes were detected and stabilization of β-catenin was identified as a common response to all hypertrophic stimuli used in this study. Hypertrophic growth was blocked by the PI3K/mTOR inhibitor PI-103.

Citing Articles

Late plasma exosome microRNA-21-5p depicts magnitude of reverse ventricular remodeling after early surgical repair of primary mitral valve regurgitation.

Pizzino F, Furini G, Casieri V, Mariani M, Bianchi G, Storti S Front Cardiovasc Med. 2022; 9:943068.

PMID: 35966562 PMC: 9373041. DOI: 10.3389/fcvm.2022.943068.

Relationship Between Circulating MicroRNAs and Left Ventricular Hypertrophy in Hypertensive Patients.

Lopes E, Paim L, Carvalho-Romano L, Marques E, Minin E, Vegian C Front Cardiovasc Med. 2022; 9:798954.

PMID: 35498018 PMC: 9043518. DOI: 10.3389/fcvm.2022.798954.

Some Peculiarities in the Dose Dependence of Separate and Combined In Vitro Cardiotoxicity Effects Induced by CdS and PbS Nanoparticles With Special Attention to Hormesis Manifestations.

Panov V, Minigalieva I, Bushueva T, Frohlich E, Meindl C, Absenger-Novak M Dose Response. 2020; 18(1):1559325820914180.

PMID: 32231470 PMC: 7088228. DOI: 10.1177/1559325820914180.

The effects of Tel2 on cardiomyocyte survival.

Yorichika N, Baba Y, Shimada B, Thakore M, Wong S, Kobayashi M Life Sci. 2019; 232:116665.

PMID: 31323273 PMC: 6698408. DOI: 10.1016/j.lfs.2019.116665.

Experimental models of cardiac physiology and pathology.

Oh J, Kho C, Hajjar R, Ishikawa K Heart Fail Rev. 2019; 24(4):601-615.

PMID: 30666533 PMC: 6561792. DOI: 10.1007/s10741-019-09769-2.

References

Antos C, McKinsey T, Frey N, Kutschke W, McAnally J, Shelton J . Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002; 99(2):907-12. PMC: 117404. DOI: 10.1073/pnas.231619298. View

Rosner M, Fuchs C, Siegel N, Valli A, Hengstschlager M . Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet. 2009; 18(17):3298-310. PMC: 2722991. DOI: 10.1093/hmg/ddp271. View

Claycomb W, Lanson Jr N, Stallworth B, Egeland D, Delcarpio J, Bahinski A . HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A. 1998; 95(6):2979-84. PMC: 19680. DOI: 10.1073/pnas.95.6.2979. View

Roshan Moniri M, Young A, Reinheimer K, Rayat J, Dai L, Warnock G . Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology. 2014; 67(2):379-86. PMC: 4329294. DOI: 10.1007/s10616-014-9692-5. View

Aoyagi T, Matsui T . Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des. 2011; 17(18):1818-24. PMC: 3337715. DOI: 10.2174/138161211796390976. View

Xiao G, Mao S, Baumgarten G, Serrano J, Jordan M, Roos K . Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res. 2001; 89(12):1122-9. DOI: 10.1161/hh2401.100742. View

Sinha D, Wang Z, Ruchalski K, Levine J, Krishnan S, Lieberthal W . Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am J Physiol Renal Physiol. 2004; 288(4):F703-13. DOI: 10.1152/ajprenal.00189.2004. View

Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H . Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007; 282(15):11221-9. PMC: 1850976. DOI: 10.1074/jbc.M611871200. View

Nishikimi T, Maeda N, Matsuoka H . The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2005; 69(2):318-28. DOI: 10.1016/j.cardiores.2005.10.001. View

10.

Lee C, Inoki K, Guan K . mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol. 2006; 47:443-67. DOI: 10.1146/annurev.pharmtox.47.120505.105359. View

11.

Lamore S, Kamendi H, Scott C, Dragan Y, Peters M . Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicol Sci. 2013; 135(2):402-13. DOI: 10.1093/toxsci/kft167. View

12.

Xi B, Wang T, Li N, Ouyang W, Zhang W, Wu J . Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J Lab Autom. 2011; 16(6):415-21. DOI: 10.1016/j.jala.2011.09.002. View

13.

Koshman Y, Piano M, Russell B, Schwertz D . Signaling responses after exposure to 5 alpha-dihydrotestosterone or 17 beta-estradiol in norepinephrine-induced hypertrophy of neonatal rat ventricular myocytes. J Appl Physiol (1985). 2010; 108(3):686-96. PMC: 2838630. DOI: 10.1152/japplphysiol.00994.2009. View

14.

Harvey P, Leinwand L . The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol. 2011; 194(3):355-65. PMC: 3153638. DOI: 10.1083/jcb.201101100. View

15.

Weiske J, Albring K, Huber O . The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity. Proc Natl Acad Sci U S A. 2007; 104(51):20344-9. PMC: 2154433. DOI: 10.1073/pnas.0703664105. View

16.

Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B . Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A. 2003; 100(8):4610-5. PMC: 153603. DOI: 10.1073/pnas.0835895100. View

17.

Molkentin J, Lu J, Antos C, Markham B, Richardson J, Robbins J . A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93(2):215-28. PMC: 4459646. DOI: 10.1016/s0092-8674(00)81573-1. View

18.

Zhang C, McKinsey T, Chang S, Antos C, Hill J, Olson E . Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002; 110(4):479-88. PMC: 4459650. DOI: 10.1016/s0092-8674(02)00861-9. View

19.

Lu J, McKinsey T, Nicol R, Olson E . Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci U S A. 2000; 97(8):4070-5. PMC: 18151. DOI: 10.1073/pnas.080064097. View

20.

Heineke J, Molkentin J . Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006; 7(8):589-600. DOI: 10.1038/nrm1983. View